.png)
Status note: the regulatory information below is date-stamped. It reflects publicly available information as of November 2026 and should be re-checked against the FDA's own pages before you act on it.
Retatrutide is an experimental weight loss drug made by Eli Lilly, and as of November 2026 it is not approved by the FDA for any use. That single sentence answers the question a lot of people are quietly asking when they search "where to buy retatrutide." In this article we walk through what the drug is, what its clinical trials actually reported, why buying it right now means buying an unapproved product of unknown quality, and what regulators are finding in the counterfeit supply. If you remember one thing, let it be this: a drug that is still investigational is not something you can legally buy as a medicine, so any "retatrutide" for sale today is either a counterfeit, a research-labeled chemical not meant for human use, or something else wearing the name.
Retatrutide is a once-weekly injectable molecule that mimics three gut hormones involved in appetite and metabolism: GIP, GLP-1, and glucagon. Hormones in this family are called incretins (in-SEE-tins), which are hormones released after you eat that help regulate appetite and blood sugar. Semaglutide, the active ingredient in Ozempic and Wegovy, copies one of these hormones, GLP-1. Tirzepatide, the active ingredient in Mounjaro and Zepbound, copies two, GLP-1 and GIP. Retatrutide copies three, which is why researchers call it a triple agonist (Lilly, 2026a). An agonist is simply a molecule that switches a receptor on, like a key that fits a lock and turns it.
DrugBrand names (approved uses)Hormones copiedApproval status (Nov 2026)SemaglutideOzempic, Wegovy, RybelsusGLP-1 (single)FDA approvedTirzepatideMounjaro, ZepboundGLP-1 + GIP (dual)FDA approvedRetatrutideNone yetGLP-1 + GIP + glucagon (triple)Investigational; BLA submission planned Q1 2027 (Lilly, 2026b)
The idea behind stacking hormones is that each one pulls a different lever. GLP-1 slows stomach emptying and increases feelings of fullness, GIP may add its own effects on appetite and fat metabolism, and glucagon is being studied for possible effects on energy expenditure. That is the theory. The theory still has to survive the trials, which brings us to what has actually been measured.
Retatrutide has been studied in a phase 2 trial and is now in a large phase 3 program called TRIUMPH. In the phase 2 trial, published in the New England Journal of Medicine, adults with obesity who took the highest dose lost about 24 percent of their body weight at 48 weeks (Whitelock et al., 2023). That result is what put retatrutide on the map.
The phase 3 results announced so far come from Lilly's own press releases describing topline data, which means the numbers are company-reported summaries of trials not yet fully published in peer-reviewed form for every study. In TRIUMPH-1, which followed 2,339 adults with obesity or overweight (and without diabetes) for 80 weeks, participants taking the three studied doses lost an average of 19.0 percent, 25.9 percent, and 28.3 percent of their body weight respectively, with the highest-dose group losing an average of about 70 pounds; among the highest-dose group, 45.3 percent of participants lost 30 percent or more of their body weight (Lilly, 2026a). A longer follow-up reported an average loss of about 30 percent at 104 weeks for the highest dose (American Journal of Managed Care [AJMC], 2026). In TRIUMPH-2, adults with type 2 diabetes and obesity or overweight lost between 12.7 and 20.8 percent depending on dose, along with meaningful A1C reductions. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6 percent, and importantly, the trial showed the drug was not harmful on major cardiovascular events but also did not prove a cardiovascular benefit (Lilly, 2026b).
Those are large effects, larger on average than the approved GLP-1 drugs produced in their own trials, and it is fair for readers to be impressed. It should be noted that these are topline, company-announced results for two of the trials and averages across groups of many people, and Lilly has stated it plans to submit a Biologics License Application to the FDA in the first quarter of 2027 (Lilly, 2026b). Announced results are not the same thing as an approved drug with FDA-reviewed labeling, manufacturing oversight, and post-market surveillance.
Search interest in retatrutide is enormous, and a lot of that interest shows up as people looking for a way to buy it before approval. Here is the practical problem. Because retatrutide has no FDA approval, there is no legal retail or pharmacy channel for it as a medicine. Compounding pharmacies cannot legally make copies of a drug that is not approved, because compounding works by copying or adjusting approved drugs, and there is nothing approved to compound from. That means every product sold as "retatrutide" online right now comes from the grey or unregulated market.
The FDA has been direct about what that market looks like. In its consumer alert on unapproved GLP-1 drugs, the agency states that unapproved versions do not undergo FDA review for safety, effectiveness, or quality before they are marketed, and it urges consumers not to purchase products sold as "for research purposes" or "not for human consumption," because their quality is unknown and they may be harmful (U.S. Food and Drug Administration [FDA], 2026a). "Research use only" on a vial of a weight loss drug is not a legal technicality that keeps you safe. It is a label that exists precisely because the product was never cleared for putting into a human body.
There is also a dosing problem that regulators have already seen play out with compounded semaglutide. The FDA has received multiple reports of adverse events, some requiring hospitalization, tied to dosing errors with unapproved injectable semaglutide, including patients self-administering incorrect amounts (FDA, 2026a). An investigational drug like retatrutide has no FDA-reviewed label with instructions, no standardized concentrations, and no pharmacist checking the prescription, so every one of those failure points is wide open.
Counterfeits are not a hypothetical with this drug class. In December 2025, the FDA warned consumers not to use counterfeit Ozempic found in the legitimate U.S. drug supply chain, in the form of dozens of seized units distributed outside the manufacturer's authorized channels; the counterfeit pens were identified by details as small as where the expiration date text sat on the label (FDA, 2025). If fake semaglutide can slip into licensed pharmacies, it is worth asking what fills the unregulated channels where retatrutide is actually sold.
The FDA's broader alert on unapproved GLP-1 drugs describes fraudulent compounded semaglutide and tirzepatide marketed in the U.S. with false label information, including labels naming pharmacies that do not exist or never made the product, and reports of injection site reactions from those products (FDA, 2026a). The agency also notes that some products use salt forms of semaglutide, for which it says it is not aware of any lawful basis for use, and that vials shipped warm or without adequate cooling may have degraded quality. For a drug like retatrutide, which has no approved reference product at all, there is no genuine article to compare a suspect vial against, which makes counterfeiting trivially easy and verification practically impossible.
The honest list here is long. Long-term safety is the headline: the reported trials followed participants for roughly 80 to 104 weeks, which is meaningful but short compared with how long people would realistically take a weight loss medication. The cardiovascular trial in people with established disease showed neither clear benefit nor clear harm on major cardiac events over its follow-up (Lilly, 2026b). Effects on less-studied outcomes, in pregnancy, in people with a history of pancreatitis or certain cancers, and over years rather than months, have not been established in published data.
Second, the announced results are topline summaries from the manufacturer, and the full peer-reviewed picture is still emerging trial by trial. Third, the trials studied specific populations: adults with obesity or overweight, type 2 diabetes, severe obesity with cardiovascular disease, and several other groups in ongoing studies such as knee osteoarthritis pain, sleep apnea, and liver disease (Lilly, 2026b). People with different health profiles, including many who are searching for the drug out of curiosity rather than medical need, were not the people in those trials. And fourth, approval timelines are plans, not promises; a submission planned for early 2027 still has to be reviewed, and review timelines can change.
If the research interests you, channel that interest into a conversation with a qualified clinician rather than a checkout page. Five questions worth bringing (our weight management, GLP-1s and body composition hub is useful background reading before the appointment):
Retatrutide's trial results are genuinely striking, and the drug may well become an approved option after the FDA reviews it. Today, though, it is investigational, so nothing legally sold as retatrutide exists as a medicine, and everything on the market under that name carries unknown quality, dosing, and counterfeit risk that the FDA has documented with this entire drug class. The people best positioned to help are a prescriber who knows your history and, for the educational background behind this article, our free Peptides in Fitness mini-course, which teaches how to read marketing claims like these before they read you. If you want the broader foundation, the Innova Vita Health and Wellness Education course covers evidence evaluation for beginners, and our guide to GLP-1 agonists and preventing muscle loss covers the nutrition side of medication-assisted weight loss.
Close the tab on any "retatrutide for sale" page. There is no legal supply of retatrutide as a medicine in the U.S. as of November 2026, so any product using that name is unapproved by definition. If a page claims otherwise, that claim itself is the red flag.
Check the FDA's own pages rather than trusting a blog, including this one. The agency maintains a consumer alert on unapproved GLP-1 drugs and a BeSafeRx resource for buying medicine online, and both are updated over time. Ten minutes there beats an hour of forum threads.
Talk to a prescriber about approved options. If weight loss medication is something you and your doctor are considering, approved drugs come with reviewed evidence, standardized dosing, and a pharmacist who can catch problems. Bring the five questions above to your next appointment.
Report problems if you see them. If you or someone you know has been harmed by an unapproved GLP-1 product, the FDA's MedWatch program exists for exactly that, and reports from the public are how many of these warnings start.
Learn the claim-evaluation basics. Stories about miracle drugs spread faster than the evidence behind them, so our free guide to evaluating health and fitness information is a useful companion to this article.
Agonist — A molecule that switches on a receptor in the body, like a key that fits a lock and turns it.
Biologics License Application (BLA) — The formal request a drug maker files with the FDA for permission to market a biologic drug in the United States.
Compounding — When a pharmacist custom-makes a medication for an individual patient, typically by adjusting or copying an approved drug.
Counterfeit drug — A fake medicine designed to look like the real thing, which may contain the wrong ingredient, the wrong amount, or no active ingredient at all.
GLP-1 receptor agonist — A drug that copies the hormone GLP-1, which increases fullness after meals and slows stomach emptying.
GIP — A gut hormone involved in fat metabolism and appetite; the second hormone copied by dual and triple agonist drugs.
Glucagon — A hormone involved in raising blood sugar and possibly energy expenditure; the third hormone copied by retatrutide.
Incretins — Hormones released by the gut after eating that help regulate appetite and blood sugar. (Used here for the family that GLP-1, GIP, and glucagon belong to.)
Investigational drug — A drug still being studied in clinical trials that has not been approved for general use.
Phase 2 / Phase 3 trial — Mid-size and large studies in people, respectively, that test whether a drug works and is safe before approval.
Topline results — Early, company-announced summary numbers from a completed trial, before full peer-reviewed publication.
American Journal of Managed Care. (2026, May 21). Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1 trial. https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial
Eli Lilly. (2026a, May 21). Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Eli Lilly. (2026b, July 23). Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
U.S. Food and Drug Administration. (2025, December 5). FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain
U.S. Food and Drug Administration. (2026a). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Whitelock, N., et al. (2023). Retatrutide, a GIP, glucagon, and GLP-1 receptor agonist, in people with obesity: A phase 2 randomised, double-blind, placebo-controlled trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Chris Bigelow holds a master’s degree in kinesiology from A.T. Still University and has taught kinesiology and exercise science at Bryan University for more than 10 years. He founded Innova Vita Fitness to make evidence-based health, fitness and research education more accessible to adult learners. His work focuses on exercise science, health literacy, sustainable behavior change and helping beginners evaluate health information more confidently.
